"use client";
import styles from "./index.module.css";

export default function Smestatus() {
  return (
    <div className={styles.details}>
      <h1>The Board of Auxesis Pharma Appoints Peter Åberg as the New CEO</h1>
      <h4>2025-02-15</h4>
      <p className={styles.ptext}>
        The Board of Auxesis has decided to appoint Peter Åberg as the new Chief
        Executive Officer (CEO) of the company. Peter has been part of the
        company’s leadership team since 2024, overseeing pharmaceutical
        development and regulatory affairs. In his new role as CEO, he will have
        overall responsibility for leading Auxesis through its continued growth
        and development.
      </p>
      <p className={styles.ptext}>
        Peter Åberg has a strong background in research, pharmaceutical
        development, and business strategy. In a previous CEO role, he was
        recognized as Dagens Industri’s Supergasell in 2022.
      </p>
      <p className={styles.ptext}>
        “I am very pleased that Peter Åberg has accepted the role as our new
        CEO,” says Roar Adelsten, founder and majority owner. “Peter possesses
        the leadership qualities required and has a deep understanding of our
        industry. I am confident that he is the right person to lead Auxesis
        into the next phase, focusing on pharmaceutical development and the
        launch of new products on the market.”
      </p>
      <p className={styles.ptext}>
        Roar Adelsten has served as CEO of Auxesis since the company was founded
        ten years ago. He is now transitioning to the role of Deputy CEO, with
        primary responsibility for business development and production. Auxesis
        is currently in an expansion phase, with new pharmaceutical products set
        to be developed and introduced to the market. At this stage,
        strengthening the leadership team with new expertise in the CEO role is
        the right strategic move.
      </p>
      <p className={styles.ptext}>
        “I am honored and excited to lead Auxesis in developing new pain relief
        pharmaceuticals for the skin,” says Peter Åberg. “I look forward to
        working with the highly skilled team already in place.”
      </p>
      <p className={styles.ptext}>
        Roar Adelsten steps down as CEO and assumes the role of Deputy CEO,
        focusing on business development and production.
      </p>
      <p className={styles.ptext}>
        Peter Åberg will officially assume the position of CEO on February 15,
        2025, while Roar Adelsten takes on his new role as Deputy CEO.
      </p>
      <p className={styles.ptext}>
        <strong>Contact:</strong>
      </p>
      <p className={styles.ptext}>
        Rune Nordström, Chairman of the Board , 070 – 602 65 20
      </p>
      <p className={styles.ptext}>Peter Åberg, CEO, 070 – 681 50 50</p>
      <div className={styles.articlesimage1}>
        <img
          className={styles.image1}
          src="/team/Peter.png"
          alt="Peter Åberg"
        />
      </div>
    </div>
  );
}
